Notably, the FDA has approved the following four CDK4/6 inhibitors: abemaciclib, palbociclib, ribociclib, and trilaciclib, which are used for the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.